CDT Equity (NASDAQ:CDT) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of CDT Equity (NASDAQ:CDT) from a sell rating to a hold rating in a research report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, CDT Equity currently has a consensus rating of “Sell”.

CDT Equity Price Performance

NASDAQ CDT opened at $1.69 on Friday. CDT Equity has a fifty-two week low of $1.62 and a fifty-two week high of $2,739.80. The stock’s 50-day moving average is $4.06 and its two-hundred day moving average is $54.19. The firm has a market cap of $1.34 million, a P/E ratio of -0.00 and a beta of 1.52.

CDT Equity (NASDAQ:CDT) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($8.71) earnings per share for the quarter.

Institutional Investors Weigh In On CDT Equity

An institutional investor recently bought a new stake in CDT Equity stock. Great Lakes Advisors LLC acquired a new position in shares of CDT Equity Inc. (NASDAQ:CDT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 18,631 shares of the company’s stock, valued at approximately $991,000. Great Lakes Advisors LLC owned about 2.96% of CDT Equity as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 3.29% of the company’s stock.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.